Cargando…

CCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans

BACKGROUND: The role of copy number variation of the CCL3L1 gene, encoding MIP1α, in contributing to the host variation in susceptibility and response to HIV infection is controversial. Here we analyse a sub-Saharan African cohort from Tanzania and Ethiopia, two countries with a high prevalence of H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aklillu, Eleni, Odenthal-Hesse, Linda, Bowdrey, Jennifer, Habtewold, Abiy, Ngaimisi, Eliford, Yimer, Getnet, Amogne, Wondwossen, Mugusi, Sabina, Minzi, Omary, Makonnen, Eyasu, Janabi, Mohammed, Mugusi, Ferdinand, Aderaye, Getachew, Hardwick, Robert, Fu, Beiyuan, Viskaduraki, Maria, Yang, Fengtang, Hollox, Edward J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829100/ https://www.ncbi.nlm.nih.gov/pubmed/24219137 http://dx.doi.org/10.1186/1471-2334-13-536

Ejemplares similares

Copy Number Variation of Fc Gamma Receptor Genes in HIV-Infected and HIV-Tuberculosis Co-Infected Individuals in Sub-Saharan Africa
por: Machado, Lee R., et al.
Publicado: (2013)

Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations
por: Ngaimisi, Eliford, et al.
Publicado: (2013)

Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations
por: Mugusi, Sabina, et al.
Publicado: (2020)

Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial
por: Amogne, Wondwossen, et al.
Publicado: (2015)

Evaluation of Patterns of Liver Toxicity in Patients on Antiretroviral and Anti-Tuberculosis Drugs: A Prospective Four Arm Observational Study in Ethiopian Patients
por: Yimer, Getnet, et al.
Publicado: (2014)

Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients
por: Yimer, Getnet, et al.
Publicado: (2011)

Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype
por: Kitabi, Eliford Ngaimisi, et al.
Publicado: (2018)

Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin
por: Mugusi, Sabina, et al.
Publicado: (2018)

Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on Efavirenz-Based HAART with or without Tuberculosis Co-Infection in Tanzania
por: Mugusi, Sabina, et al.
Publicado: (2012)

Early or deferred initiation of efavirenz during rifampicin‐based TB therapy has no significant effect on CYP3A induction in TB‐HIV infected patients
por: Aklillu, Eleni, et al.
Publicado: (2020)

Anti-Tuberculosis Therapy-Induced Hepatotoxicity among Ethiopian HIV-Positive and Negative Patients
por: Yimer, Getnet, et al.
Publicado: (2008)

Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity
por: Petros, Zelalem, et al.
Publicado: (2016)

HLA-B(*)57 Allele Is Associated with Concomitant Anti-tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians
por: Petros, Zelalem, et al.
Publicado: (2017)

Prevalence and risk factors for efavirenz-based antiretroviral treatment–associated severe vitamin D deficiency: A prospective cohort study
por: Nylén, Hanna, et al.
Publicado: (2016)

The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment
por: Maganda, Betty A, et al.
Publicado: (2015)

Constitutive androstane receptor and pregnane X receptor genotype influence efavirenz plasma concentration and CYP2B6 enzyme activity
por: Petros, Zelalem, et al.
Publicado: (2022)

Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania
por: Sungi, Selemani Saidi, et al.
Publicado: (2018)

Optimal single sampling time-point for monitoring of praziquantel exposure in children
por: Mnkugwe, Rajabu Hussein, et al.
Publicado: (2021)

Genetic and non‐genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus‐1‐infected children in Ethiopia
por: Chala, Adugna, et al.
Publicado: (2023)

Adherence to combination antiretroviral therapy among orphaned children in Dar es Salaam, Tanzania
por: Mugusi, Sabina F., et al.
Publicado: (2019)

Effect of Dihydroartemisinin-Piperaquine on the Pharmacokinetics of Praziquantel for Treatment of Schistosoma mansoni Infection
por: Minzi, Omary Mashiku, et al.
Publicado: (2021)

Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study
por: Chala, Adugna, et al.
Publicado: (2021)

Effect of Rumex Abyssinicus on preneoplastic lesions in dimethylhydrazine induced colon carcinogenesis in rats
por: Girma, Biniyam, et al.
Publicado: (2015)

Minority Drug-Resistant HIV-1 Variants in Treatment Naïve East-African and Caucasian Patients Detected by Allele-Specific Real-Time PCR
por: Ekici, Halime, et al.
Publicado: (2014)

Comparison of bioavailability between the most available generic tablet formulation containing artemether and lumefantrine on the Tanzanian market and the innovator’s product
por: Minzi, Omary MS, et al.
Publicado: (2013)

Inhaler Non-Adherence, Associated Factors and Asthma Control among Asthma Patients in a Tertiary Level Hospital in Tanzania
por: Shayo, Grace A., et al.
Publicado: (2022)

Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania
por: Barry, Abbie, et al.
Publicado: (2020)

Vitamin D Status and Association of VDR Genetic Polymorphism to Risk of Breast Cancer in Ethiopia
por: Ahmed, Jemal Hussien, et al.
Publicado: (2019)

Short-term impact of celebrating the international clinical trial day: experience from Ethiopia
por: Fekadu, Abebaw, et al.
Publicado: (2017)

Anemia Is a Strong Predictor of Wasting, Disease Severity, and Progression, in Clinical Tuberculosis (TB)
por: Ashenafi, Senait, et al.
Publicado: (2022)

CYP2J2(∗)7 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients
por: Ahmed, Jemal Hussien, et al.
Publicado: (2019)

HIV/AIDS Clinical Manifestations and their Implication for Patient Clinical Staging in Resource Limited Settings in Tanzania
por: Boniphace, Idindili, et al.
Publicado: (2011)

The Impact of First-Line Anti-Tubercular Drugs’ Pharmacokinetics on Treatment Outcome: A Systematic Review
por: Sileshi, Tesemma, et al.
Publicado: (2021)

Effect of Genetic Variations in Drug-Metabolizing Enzymes and Drug Transporters on the Pharmacokinetics of Rifamycins: A Systematic Review
por: Sileshi, Tesemma, et al.
Publicado: (2022)

Haptoglobin (HP) and Haptoglobin-related protein (HPR) copy number variation, natural selection, and trypanosomiasis
por: Hardwick, Robert J., et al.
Publicado: (2013)

Prevalence and Correlates of Asymptomatic Malaria and Anemia on First Antenatal Care Visit among Pregnant Women in Southeast, Tanzania
por: Mlugu, Eulambius M., et al.
Publicado: (2020)

Elevated levels of circulating CDH5 and FABP1 in association with human drug‐induced liver injury
por: Mikus, Maria, et al.
Publicado: (2016)

Daily Nutritional Supplementation with Vitamin D(3) and Phenylbutyrate to Treatment-Naïve HIV Patients Tested in a Randomized Placebo-Controlled Trial
por: Ashenafi, Senait, et al.
Publicado: (2019)

Comparison of malaria treatment outcome of generic and innovator’s anti-malarial drugs containing artemether–lumefantrine combination in the management of uncomplicated malaria amongst Tanzanian children
por: Kilonzi, Manase, et al.
Publicado: (2019)

Efficacy and safety of praziquantel and dihydroartemisinin piperaquine combination for treatment and control of intestinal schistosomiasis: A randomized, non-inferiority clinical trial
por: Mnkugwe, Rajabu Hussein, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2fp6robk33av3l4boi3anrrqss